Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 1,059,937 | 1,029,373 | 1,099,843 | 989,157 | 973,131 |
| Cost of Goods | 660,960 | 651,719 | 700,959 | 618,934 | 616,405 |
| Gross Profit | 398,977 | 377,654 | 398,884 | 370,223 | 356,726 |
| Operating Expenses | 234,992 | 210,481 | 236,033 | 220,181 | 169,720 |
| Operating Income | 164,945 | 167,892 | 163,810 | 150,976 | 187,411 |
| Interest Expense | 35,044 | 34,380 | 34,779 | 11,375 | 3,703 |
| Other Income | -1,237 | -2,471 | 115,890 | -16,494 | -39,595 |
| Pre-tax Income | 128,664 | 131,041 | 244,921 | 123,107 | 144,113 |
| Income Tax | 29,221 | 27,087 | 55,815 | 25,495 | 33,449 |
| Net Income Continuous | 99,443 | 103,954 | 189,106 | 97,612 | 110,664 |
| Minority Interests | 2,423 | 823 | 1,696 | 1,139 | 1,343 |
| Net Income | $97,020 | $103,131 | $187,410 | $96,473 | $109,321 |
| EPS Basic Total Ops | 1.89 | 2.02 | 3.68 | 1.90 | 2.15 |
| EPS Basic Continuous Ops | 1.94 | 2.03 | 3.72 | 1.92 | 2.18 |
| EPS Diluted Total Ops | 1.89 | 2.01 | 3.66 | 1.88 | 2.13 |
| EPS Diluted Continuous Ops | 1.93 | 2.02 | 3.69 | 1.90 | 2.16 |
| EPS Diluted Before Non-Recurring Items | 2.69 | 2.78 | 2.98 | N/A | N/A |
| EBITDA(a) | $242,616 | $244,961 | $241,355 | $225,581 | $263,832 |